Phase I/II Clinical Study to Evaluate the Safety, Tolerability and Efficacy of LY-M003 Injection in Adult Patients With Wilson's Disease

Phase 2Not Yet RecruitingNCT07641140

Lingyi Biotech Co., Ltd.18 enrolled

Overview

This is a multicenter, open-label, single-arm, single-dose Phase I/II clinical study. It aims to evaluate the safety, tolerability, efficacy, immunogenicity, pharmacodynamic (PD) and pharmacokinetic (PK) profiles of LY-M003 Injection in patients with Wilson's Disease (WD). The Phase I/II study consists of a main study phase and a long-term follow-up phase. The main study phase includes an 8-week screening period and a 52-week follow-up period after infusion. The long-term follow-up phase starts at Week 53 and lasts until 5 years post-infusion. The study pre-specified two dose cohorts, consisting of one main dose cohort and one de-escalation dose cohort: Dose Cohort 1 (4.0 × 10¹³ vg/kg) and the de-escalation dose cohort (2.0 × 10¹³ vg/kg). Three subjects will be enrolled in each dose cohort.Dose Cohort 1 serves as the starting dose. After the first subject receives the study drug, a minimum 28-day DLT observation period must be completed to confirm safety before enrolling subsequent subjects.All three subjects in Dose Cohort 1 have completed the 28-day (Day 28) DLT observation period following LY-M003 infusion. The Safety Review Committee (SRC) will make a comprehensive assessment to determine whether to proceed to the dose expansion phase at the dose level of 4.0 × 10¹³ vg/kg.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Wilson's Disease

Interventions

LY-M003 InjectionGENETIC

Phase 1: Participants receive a single, peripheral intravenous (IV) infusion of LY-M003 at dose group 1.The dose for Dose Group 1 is 4.0 × 10¹³ vg/kg.All participants are administered the drug once via intravenous injection.

LY-M003 InjectionGENETIC

Phase 1: Participants receive a single, peripheral intravenous (IV) infusion of LY-M003 at de-escalation dose.The dose for de-escalation dose is 2.0 × 10¹³ vg/kg.All participants are administered the drug once via intravenous injection.

LY-M003 InjectionGENETIC

Phase 2: Participants receive a single, peripheral intravenous (IV) infusion of LY-M003 at dose group 1.The dose for dose group 1 is 4.0 × 10¹³ vg/kg.All participants are administered the drug once via intravenous injection.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 60 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. The subject fully comprehends the purpose, design, methods and possible adverse events of the study, agrees to participate voluntarily and signs the informed consent form (ICF). 2. Patients with confirmed diagnosis of Wilson's disease (WD). 3. Subjects with Wilson's disease (WD) confirmed by laboratory testing to have biallelic ATP7B gene mutation or deletion. 4. The subjects are treated patients with Wilson's disease (WD) who have received standard therapy (e.g., D-penicillamine or zinc acetate) continuously for at least 6 months prior to screening. 5. Subjects have maintained a low-copper diet for at least 6 consecutive months prior to screening and will continue this dietary restriction throughout the study. 6. Subjects must agree to refrain from donating blood, organs, tissues or cells at any time after treatment. 7. Female subjects of childbearing potential (WOCBP) must have a negative pregnancy test. 8. Subjects and their partners must have no plans for pregnancy from screening through 6 months after study completion, and will voluntarily use effective contraception (e.g., abstinence, condoms). Subjects shall not plan to donate sperm or ova. Exclusion Criteria: 1. AAV8 neutralizing antibody titer \> 1:10 . 2. History of active gastrointestinal bleeding within the past 3 months. 3. Decompensated liver cirrhosis or advanced liver disease presenting with portal hypertension, ascites, splenomegaly, esophageal varices, hepatic encephalopathy, etc. 4. Subjects with other concomitant liver diseases as judged by the investigator, including autoimmune hepatitis, alcoholic liver disease, primary biliary cholangitis, primary sclerosing cholangitis, and/or drug- or toxin-induced liver disease. 5. Subjects with severe hypersplenism complicated and requiring splenectomy as assessed by the investigator. 6. Model for End-Stage Liver Disease (MELD) score \> 13. 7. Other disorders of copper metabolism, such as chronic cholestatic liver diseases, disorders of glycosylation, copper metabolism disorders, etc. 8. A history of non-compliance with copper chelators or zinc agents as assessed by the investigator within 6 months prior to screening. 9. Previously treated WD subjects with ALT and/or AST levels more than 5 times the upper limit of normal (ULN). 10. Subjects with severe neurological deficits or impairments that, in the investigator's judgment, compromise their safety and/or ability to participate in the study. 11. Hemoglobin \< 90g/L. 12. Subjects with positive hepatitis B surface antigen (HBsAg), positive hepatitis C virus (HCV) antibody, positive human immunodeficiency virus (HIV) antibody or positive treponema pallidum antibody. 13. Subjects with end-stage renal disease on dialysis (Chronic Kidney Disease Stage 3 and above), or creatinine clearance \< 60 mL/min. 14. Severe hyperlipidemia (triglycerides \>1000 mg/dL); 15. Subjects who have received or plan to undergo bone marrow transplantation, hematopoietic stem cell transplantation and/or major organ transplantation, including but not limited to liver transplantation and renal transplantation. 16. Subjects with clinically diagnosed severe cardiovascular diseases or those deemed by the investigator to have such conditions (e.g., New York Heart Association \[NYHA\] heart failure classification ≥ Class 3). 17. Subjects with uncontrolled concomitant diseases or infectious diseases as assessed by the investigator. 18. Subjects who are allergic to any ingredient of LY-M003 Injection. 19. Prior receipt of any type of gene therapy or cell therapy. 20. Use of systemic immunosuppressants or steroids within 3 months prior to administration (except for prophylactic immunosuppressive therapy specified in the protocol). 21. History of cancer within 5 years prior to screening, excluding completely resected non-melanoma skin cancer, non-metastatic prostate cancer and fully cured ductal carcinoma in situ. 22. Received live attenuated vaccines within 4 months prior to screening, or planned to receive such vaccines during the clinical trial. 23. Received treatment or intervention with other investigational drugs or study devices within 28 days or 5 half-lives (for drugs only) prior to screening, whichever is longer. 24. Pregnant women (or women planning pregnancy) or breastfeeding women. 25. Other conditions that, in the investigator's opinion, render the subject ineligible for study participation.

Locations (1)

The First Affiliated Hospital, Zhejiang University School of Medicine

Hangzhou, Zhejiang, China

Outcomes

Primary Outcomes

Phase I:The incidence of dose-limiting toxicity (DLT) events adjudicated by the Safety Review Committee (SRC) within at least 28 days after LY-M003 infusion.

The incidence of DLT will be assessed using CTCAE 6.0.

Time frame: Within 28 days after infusion of LY-M003 Injection

The incidence of treatment-emergent adverse events (AEs), adverse events of special interest (AESIs) and serious adverse events (SAEs) related to LY-M003 within 52 weeks after infusion.

Assessment will be conducted via 12-lead ECG, laboratory tests(blood routine, blood biochemistry, coagulation function, stool routine, urine routine), vital signs (blood pressure, pulse, respiratory rate, body temperature) and physical examination.

Time frame: 5 years

Secondary Outcomes

Percentage reduction in the dosage of standard of care (SoC) medications within 52 weeks after administration.

Assessment will be based on the percentage of participants who underwent standard dose reduction after infusion.

Time frame: Within 52 weeks after administration

Number and proportion of subjects who discontinued standard of care (SoC) medications within 52 weeks after administration.

Assessment will be based on the number and percentage of participants who discontinued standard treatment medications.

Time frame: Within 52 weeks after administration

Duration (in treatment weeks) of consecutive discontinuation of SoC medications among the above subjects.

Assessment will be based on the number of consecutive cycles during which participants discontinued standard medications.

Time frame: Within 52 weeks after administration

Change in serum non-caeruloplasmin-bound copper (NCC) from baseline within 52 weeks after administration

Central Contacts

Rihong He

CONTACT

+8619121572057 rihong.he@lingyimed.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Assessment will be based on changes in serum non-ceruloplasmin-bound copper from baseline.

Time frame: Within 52 weeks after administration

Change in serum ceruloplasmin level from baseline within 52 weeks after administration

Assessment will be based on changes in serum ceruloplasmin level from baseline.

Time frame: Within 52 weeks after administration

Change in serum ceruloplasmin activity level from baseline within 52 weeks after administration

Assessment will be based on changes in erum ceruloplasmin activity level from baseline.

Time frame: Within 52 weeks after administration

Change in 24-hour urinary copper content from baseline at each follow-up time point within 52 weeks after administration

Assessment will be based on changes in 24-hour urinary copper content from baseline.

Time frame: Within 52 weeks after administration

Change in serum total copper from baseline within 52 weeks after administration

Assessment will be based on changes in serum total copper from baseline

Time frame: Within 52 weeks after administration

Change from baseline in total score of the neurological subscale of the Unified Wilson's Disease Rating Scale (UWDRS) within 52 weeks after administration

Assess the change from baseline in the total score of Part I of the Unified Wilson's Disease Rating Scale (UWDRS). Part I of the UWDRS is the neurological subscale, with a total score ranging from 0 to 208. Higher scores indicate more severe disease and poorer functional status.

Time frame: Within 52 weeks after administration

Change from baseline in hepatic subscale score of the Unified Wilson's Disease Rating Scale (UWDRS) within 52 weeks after administration

Assess the change from baseline in the total score of Part II of the Unified Wilson's Disease Rating Scale (UWDRS). Part II is the hepatic subscale, with a total score ranging from 0 to 36. Higher scores indicate more severe disease and poorer functional status.

Time frame: Within 52 weeks after administration

Change from baseline in psychiatric subscale score of the Unified Wilson's Disease Rating Scale (UWDRS) within 52 weeks after administration

Assess the change from baseline in the total score of Part III of the Unified Wilson's Disease Rating Scale (UWDRS). Part III is the psychiatric subscale, with a total score ranging from 0 to 76. Higher scores indicate more severe disease and poorer functional status.

Time frame: Within 52 weeks after administration

Change from baseline in individual item/subscale scores (speech, handwriting, standing and gait) of the Unified Wilson's Disease Rating Scale (UWDRS) within 52 weeks after administration

Assessment will be based on changes from baseline in individual item/subscale scores (speech, handwriting, standing and gait) of the Unified Wilson's Disease Rating Scale (UWDRS).The total score for speech, writing, standing and gait each ranges from 0 to 4. Higher scores indicate more severe conditions.

Time frame: Within 52 weeks after administration

Change in ALT and AST from baseline within 52 weeks after administration

Assessment will be based on changes in ALT and AST from baseline

Time frame: Within 52 weeks after administration

Change in liver stiffness from baseline within 52 weeks after administration

Assessment will be based on changes in liver stiffness from baseline.Liver stiffness is measured by liver and gallbladder ultrasonography combined with ultrasound elastography, with the unit of kPa. * \<5.8 kPa: No liver fibrosis (F0) * 5.8 \~ 6.8 kPa: Mild liver fibrosis (F1) * 6.8 \~ 9.1 kPa: Moderate liver fibrosis (F2) * 9.1 \~ 10.3 kPa: Severe liver fibrosis (F3) * \>10.3 kPa: Liver cirrhosis (F4) Higher values indicate more advanced liver fibrosis or cirrhosis.

Time frame: Within 52 weeks after administration

Change in Kayser-Fleischer (K-F) rings from baseline within 52 weeks after administration

Assessment will be based on changes in Kayser-Fleischer (K-F) rings from baseline

Time frame: within 52 weeks after administration

Long-term follow-up study: Percentage reduction in standard of care (SoC) medication dosage after 52 weeks of administration

Assessment will be based on the percentage of participants who underwent standard dose reduction after infusion